{"pii": "S107476132200560X", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S107476132200560X-fx1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S107476132200560X/fx1/DOWNSAMPLED/image/jpeg/66258b38d19bda564b3018e1473d6920/fx1.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "65273"}, {"#name": "pixel-height", "_": "375"}, {"#name": "pixel-width", "_": "375"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S107476132200560X-fx1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S107476132200560X/fx1/THUMBNAIL/image/gif/d12c3765b8955eb091b1fff033ea4b20/fx1.sml"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "16526"}, {"#name": "pixel-height", "_": "164"}, {"#name": "pixel-width", "_": "164"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S107476132200560X-fx1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S107476132200560X/HIGHRES/image/jpeg/a6e38583c58a161593315d6a802c774b/fx1_lrg.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "357098"}, {"#name": "pixel-height", "_": "996"}, {"#name": "pixel-width", "_": "996"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Summary"}, {"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "_": "Increased immune evasion by SARS-CoV-2 variants of concern highlights the need for new therapeutic neutralizing antibodies. Immunization with nanoparticles co-displaying spike receptor-binding domains (RBDs) from eight sarbecoviruses (mosaic-8 RBD-nanoparticles) efficiently elicits cross-reactive polyclonal antibodies against conserved sarbecovirus RBD epitopes. Here, we identified monoclonal antibodies (mAbs) capable of cross-reactive binding and neutralization of animal sarbecoviruses and SARS-CoV-2 variants by screening single mouse B cells secreting IgGs that bind two or more sarbecovirus RBDs. Single-particle cryo-EM structures of antibody-spike complexes, including a Fab-Omicron complex, mapped neutralizing mAbs to conserved class 1/4 RBD epitopes. Structural analyses revealed neutralization mechanisms, potentials for intra-spike trimer cross-linking by IgGs, and induced changes in trimer upon Fab binding. In addition, we identified a mAb-resembling Bebtelovimab, an EUA-approved human class 3 anti-RBD mAb. These results support using mosaic RBD-nanoparticle vaccination to generate and identify therapeutic pan-sarbecovirus and pan-variant mAbs."}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0015"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "link", "$": {"xmlns:xlink": true, "locator": "fx1", "type": "simple", "href": "pii:S107476132200560X/fx1", "id": "aep-link-id8"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "author-highlights", "id": "abs0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0020"}, "_": "Highlights"}, {"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "$$": [{"#name": "list", "$": {"id": "ulist0010"}, "$$": [{"#name": "list-item", "$": {"id": "u0010"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0010", "view": "all"}, "_": "mAbs elicited in mosaic nanoparticle-immunized mice exhibit cross-reactive recognition"}]}, {"#name": "list-item", "$": {"id": "u0015"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0015", "view": "all"}, "_": "Fab-spike cryo-EM structures show targeting of conserved class 1/4 and 3 RBD epitopes"}]}, {"#name": "list-item", "$": {"id": "u0020"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0020", "view": "all"}, "_": "Fab-spike structures show increased trimer openness and potential intra-spike binding"}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "teaser", "id": "abs0025", "view": "all"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0025", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0025", "view": "all"}, "_": "Sarbecovirus spike receptor-binding domains (RBDs) include conserved and variable epitopes, suggesting that antibodies against conserved regions would protect against future sarbecovirus spillovers and SARS-CoV-2 variants. Fan et\u00a0al. structurally and functionally characterized monoclonal antibodies elicited by a mosaic-8 RBD-nanoparticle vaccine candidate, demonstrating cross-reactive binding, neutralization, and targeting of desired epitopes."}]}]}]}}